# Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)

> **NCT05909683** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hellenic Institute for the Study of Sepsis** · enrollment: 190 (estimated)

## Conditions studied

- Sepsis

## Interventions

- **DIAGNOSTIC_TEST:** Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT05909683
- **Lead sponsor:** Hellenic Institute for the Study of Sepsis
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-19
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-04-15
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05909683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05909683, "Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05909683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*